Zacks: Brokerages Expect Tcr2 Therapeutics Inc (NASDAQ:TCRR) Will Post Earnings of -$0.61 Per Share

Wall Street analysts predict that Tcr2 Therapeutics Inc (NASDAQ:TCRR) will report earnings of ($0.61) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Tcr2 Therapeutics’ earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.94). The company is scheduled to issue its next quarterly earnings report on Monday, August 12th.

On average, analysts expect that Tcr2 Therapeutics will report full-year earnings of ($6.13) per share for the current fiscal year, with EPS estimates ranging from ($6.86) to ($4.75). For the next fiscal year, analysts expect that the company will report earnings of ($3.19) per share, with EPS estimates ranging from ($3.84) to ($2.92). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Tcr2 Therapeutics.

Tcr2 Therapeutics (NASDAQ:TCRR) last announced its earnings results on Monday, May 13th. The company reported ($4.85) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($4.47).

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Farmland Partners from a “hold” rating to a “sell” rating in a research note on Friday. Roth Capital assumed coverage on shares of Tcr2 Therapeutics in a research note on Friday, May 31st. They set a “neutral” rating and a $16.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Tcr2 Therapeutics presently has an average rating of “Buy” and a consensus price target of $27.80.

Shares of NASDAQ TCRR traded down $0.11 during trading on Tuesday, reaching $12.76. The company had a trading volume of 10,820 shares, compared to its average volume of 39,813. Tcr2 Therapeutics has a 52 week low of $12.59 and a 52 week high of $25.47. The stock has a market cap of $311.22 million and a PE ratio of -0.13. The business’s 50 day moving average is $14.60.

A number of large investors have recently modified their holdings of the business. Laurion Capital Management LP bought a new stake in Tcr2 Therapeutics in the first quarter valued at approximately $417,000. Dean Capital Investments Management LLC acquired a new position in shares of Tcr2 Therapeutics in the first quarter valued at approximately $694,000. Redmile Group LLC acquired a new position in shares of Tcr2 Therapeutics in the first quarter valued at approximately $28,686,000. Finally, MPM Asset Management LLC acquired a new position in shares of Tcr2 Therapeutics in the first quarter valued at approximately $67,192,000. 33.26% of the stock is owned by hedge funds and other institutional investors.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Featured Story: What are the benefits of a portfolio tracker?

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit